Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance.
Dietary habits
Esophageal squamous cell carcinoma
Interleukin-12
Interleukin-13
Interleukin-8
Survival analysis
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
23 Jun 2024
23 Jun 2024
Historique:
accepted:
27
04
2024
medline:
24
6
2024
pubmed:
24
6
2024
entrez:
23
6
2024
Statut:
aheadofprint
Résumé
Interleukin-8 (IL8), Interleukin-12 (IL12) and Interleukin-13 (IL13) are cytokines that play regulatory role in cancer pathogenesis. We analysed their expression profile to evaluate as molecular biomarkers of esophageal squamous cell carcinoma (ESCC) and their association with different parameters and patient survival. Expression analysis was performed by Real time quantitative polymerase chain reaction and receiver operating characteristic (ROC) curve analysis was done. The expression profiles were associated with different clinicopathological and dietary factors. Survival and hazard analysis were also performed. IL8 expression showed upregulation in tissue (p = 0.000) and blood samples (p = 0.481), IL12 expression showed downregulation in tissue samples (p = 0.064) and upregulation in blood samples (p = 0.689) and IL13 expression showed upregulation in tissue (p = 0.000) and blood samples (p = 0.006). IL13 expression in tissue showed the highest area under the curve (AUC) value (0.773) for ESCC diagnosis, followed by IL8 expression in tissue (0.704) and IL13 expression in blood (0.643). This study also reveals the correlation of studied cytokines in tissue and blood level. Different clinicopathological and dietary factors showed significant association (p < 0.05) with IL8, IL12 and IL13 expression and with survival of ESCC patients. IL8 expression in blood and IL12 expression in tissue and blood showed significant association (p < 0.05) with patient survival. Altered expression of IL8, IL12 and IL13 may be associated with ESCC progression. Overexpression of IL8 and IL13 in tissue samples may be potential biomarkers for ESCC screening. Additionally, both survival and hazard analysis data indicate the effects of different parameters on the prognosis of ESCC patients.
Identifiants
pubmed: 38910194
doi: 10.1007/s12029-024-01063-1
pii: 10.1007/s12029-024-01063-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Zhu H, Wang Z, Deng B, et al. Epidemiological landscape of esophageal cancer in Asia: results from GLOBOCAN 2020. Thorac Cancer. 2023;14(11):992–1003. https://doi.org/10.1111/1759-7714.14835 .
doi: 10.1111/1759-7714.14835
pubmed: 36918204
pmcid: 10101841
Fernández-Montes A, Alcaide J, Alsina M, et al. SEOM-GEMCAD-TTD Clinical guideline for the diagnosis and treatment of esophageal cancer. Clin Transl Oncol. 2021;24(4):658–69. https://doi.org/10.1007/s12094-022-02801-2 .
doi: 10.1007/s12094-022-02801-2
Teixeira Farinha H, Digklia A, Schizas D, Demartines N, Schäfer M, Mantziari S. Immunotherapy for esophageal cancer: state-of-the art in 2021. Cancers (Basel). 2022;14(3):554. https://doi.org/10.3390/cancers14030554 .
doi: 10.3390/cancers14030554
pubmed: 35158822
Sheikh M, Roshandel G, McCormack V, Malekzadeh R. Current status and future prospects for esophageal cancer. Cancers (Basel). 2023;15(3):765. https://doi.org/10.3390/cancers15030765 .
doi: 10.3390/cancers15030765
pubmed: 36765722
Chu LY, Peng YH, Weng XF, Xie JJ, Xu YW. Blood-based biomarkers for early detection of esophageal squamous cell carcinoma. World J Gastroenterol. 2020;26(15):1708–25. https://doi.org/10.3748/wjg.v26.i15.1708 .
doi: 10.3748/wjg.v26.i15.1708
pubmed: 32351288
pmcid: 7183865
Battaglin F, Naseem M, Puccini A, Lenz HJ. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int. 2018;18:99. https://doi.org/10.1186/s12935-018-0594-z .
doi: 10.1186/s12935-018-0594-z
pubmed: 30008616
pmcid: 6042434
Hassan MS, Cwidak N, Awasthi N, von Holzen U. Cytokine interaction with cancer-associated fibroblasts in esophageal cancer. Cancer Control. 2022;29:10732748221078470. https://doi.org/10.1177/10732748221078470 .
doi: 10.1177/10732748221078470
pubmed: 35442094
pmcid: 9024076
Kartikasari AER, Huertas CS, Mitchell A, Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142. https://doi.org/10.3389/fonc.2021.692142 .
doi: 10.3389/fonc.2021.692142
pubmed: 34307156
pmcid: 8294036
Cavazzoni A, Digiacomo G. Role of cytokines and other soluble factors in tumor development: rationale for new therapeutic strategies. Cells. 2023;12(21):2532. https://doi.org/10.3390/cells12212532 .
doi: 10.3390/cells12212532
pubmed: 37947610
pmcid: 10647643
Xiong X, Liao X, Qiu S, et al. CXCL8 in tumor biology and its implications for clinical translation. Front Mol Biosci. 2022;9:723846. https://doi.org/10.3389/fmolb.2022.723846 .
doi: 10.3389/fmolb.2022.723846
pubmed: 35372515
pmcid: 8965068
Andrejkovits ÁV, Huțanu A, Susányi EJ, Negrea V, Văsieșiu AM. The prognostic utility of cytokines in hospitalized COVID-19 patients. J Crit Care Med (Targu Mures). 2023;9(4):208–17. https://doi.org/10.2478/jccm-2023-0025 .
doi: 10.2478/jccm-2023-0025
pubmed: 37969879
Czajka-Francuz P, Cisoń-Jurek S, Czajka A, et al. Systemic interleukins’ profile in early and advanced colorectal cancer. Int J Mol Sci. 2021;23(1):124. https://doi.org/10.3390/ijms23010124 .
doi: 10.3390/ijms23010124
pubmed: 35008550
pmcid: 8745135
Fu X, Wang Q, Du H, Hao H. CXCL8 and the peritoneal metastasis of ovarian and gastric cancer. Front Immunol. 2023;14:1159061. https://doi.org/10.3389/fimmu.2023.1159061 .
doi: 10.3389/fimmu.2023.1159061
pubmed: 37377954
pmcid: 10291199
Zou D, Song A, Yong W. Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis. Front Oncol. 2023;13:1176574. https://doi.org/10.3389/fonc.2023.1176574 .
doi: 10.3389/fonc.2023.1176574
pubmed: 37621675
pmcid: 10446970
Viola NT, Glassbrook JE, Kalluri JR, et al. Evaluation of an ImmunoPET Tracer for IL-12 in a preclinical model of Inflammatory Immune responses. Front Immunol. 2022;13:870110. https://doi.org/10.3389/fimmu.2022.870110 .
doi: 10.3389/fimmu.2022.870110
pubmed: 35634303
pmcid: 9130849
Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL. Interleukin-12 as an in situ cancer vaccine component: a review. Cancer Immunol Immunother. 2022;71(9):2057–65. https://doi.org/10.1007/s00262-022-03144-1 .
doi: 10.1007/s00262-022-03144-1
pubmed: 35024897
pmcid: 9276836
Nyati S, Stricker H, Barton KN, et al. A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma. PLoS ONE. 2023;18(9):e0291315. https://doi.org/10.1371/journal.pone.0291315 .
doi: 10.1371/journal.pone.0291315
pubmed: 37713401
pmcid: 10503775
Nirschl CJ, Brodkin HR, Domonkos C, et al. mWTX-330, an IL-12 INDUKINE molecule, activates and reshapes tumor-infiltrating CD8+ T and NK cells to generate antitumor immunity. Cancer Immunol Res. 2023;11(7):962–77. https://doi.org/10.1158/2326-6066.CIR-22-0705 .
doi: 10.1158/2326-6066.CIR-22-0705
pubmed: 37074216
pmcid: 10320472
Cirella A, Luri-Rey C, Di Trani CA, et al. Novel strategies exploiting interleukin-12 in cancer immunotherapy. Pharmacol Ther. 2022;239:108189. https://doi.org/10.1016/j.pharmthera.2022.108189 .
doi: 10.1016/j.pharmthera.2022.108189
pubmed: 35430292
Di Trani CA, Cirella A, Arrizabalaga L, et al. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure. Mol Ther Nucleic Acids. 2023;33:599–616. https://doi.org/10.1016/j.omtn.2023.07.020 .
doi: 10.1016/j.omtn.2023.07.020
pubmed: 37637207
pmcid: 10450355
Roeb E. Interleukin-13 (IL-13)-A pleiotropic cytokine involved in wound healing and fibrosis. Int J Mol Sci. 2023;24(16):12884. https://doi.org/10.3390/ijms241612884 .
doi: 10.3390/ijms241612884
pubmed: 37629063
pmcid: 10454844
Song X, Traub B, Shi J, Kornmann M. Possible roles of Interleukin-4 and -13 and their receptors in gastric and colon cancer. Int J Mol Sci. 2021;22(2):727. https://doi.org/10.3390/ijms22020727 .
doi: 10.3390/ijms22020727
pubmed: 33450900
pmcid: 7828336
Shi J, Shen X, Kang Q, Yang X, et al. Loss of Interleukin-13-receptor-alpha-1 induces apoptosis and promotes EMT in pancreatic Cancer. Int J Mol Sci. 2022;23(7):3659. https://doi.org/10.3390/ijms23073659 .
doi: 10.3390/ijms23073659
pubmed: 35409019
pmcid: 8998778
Ahn SW, Lee CM, Kang MA, et al. IL4Rα and IL13Rα1 are involved in the development of human gallbladder cancer. J Pers Med. 2022;12(2):249. https://doi.org/10.3390/jpm12020249 .
doi: 10.3390/jpm12020249
pubmed: 35207737
pmcid: 8875933
Fousek K, Horn LA, Palena C. Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther. 2021;219:107692. https://doi.org/10.1016/j.pharmthera.2020.107692 .
doi: 10.1016/j.pharmthera.2020.107692
pubmed: 32980444
Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer. 2019;1871(2):289–312. https://doi.org/10.1016/j.bbcan.2019.01.005 .
doi: 10.1016/j.bbcan.2019.01.005
pubmed: 30703432
Maynard JP, Ertunc O, Kulac I, Baena-Del Valle JA, De Marzo AM, Sfanos KS. IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol Cancer Res. 2020;18(1):153–65. https://doi.org/10.1158/1541-7786.MCR-19-0595 .
doi: 10.1158/1541-7786.MCR-19-0595
pubmed: 31604846
Liao H, Li H, Song J, et al. Expression of the prognostic marker IL-8 correlates with the immune signature and epithelial-mesenchymal transition in breast cancer. J Clin Lab Anal. 2023;37(3):e24797. https://doi.org/10.1002/jcla.24797 .
doi: 10.1002/jcla.24797
pubmed: 36725216
pmcid: 9978063
Lin L, Li L, Ma G, Kang Y, Wang X, He J. Overexpression of IL-8 and Wnt2 is associated with prognosis of gastric cancer. Folia Histochem Cytobiol. 2022;60(1):66–73. https://doi.org/10.5603/FHC.a2022.0002 .
doi: 10.5603/FHC.a2022.0002
pubmed: 35037695
Yang F, Liu XQ, He JZ, et al. Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4. J Cell Mol Med. 2022;26(8):2363–76. https://doi.org/10.1111/jcmm.17257 .
doi: 10.1111/jcmm.17257
pubmed: 35224833
pmcid: 8995457
Ebeling S, Kowalczyk A, Perez-Vazquez D, Mattiola I. Regulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells. Front Oncol. 2023;13:1171794. https://doi.org/10.3389/fonc.2023.1171794 .
doi: 10.3389/fonc.2023.1171794
pubmed: 37234993
pmcid: 10206118
Capone F, Guerriero E, Sorice A, Colonna G, Ciliberto G, Costantini S. Serum cytokinome profile evaluation: a tool to define new diagnostic and prognostic markers of cancer using multiplexed bead-based immunoassays. Mediators Inflamm. 2016;2016:3064643. https://doi.org/10.1155/2016/3064643 .
doi: 10.1155/2016/3064643
pubmed: 28050120
pmcid: 5168457
Barrera L, Montes-Servín E, Barrera A, et al. Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol. 2015;26(2):428–35. https://doi.org/10.1093/annonc/mdu549 .
doi: 10.1093/annonc/mdu549
pubmed: 25467015
Manca MA, Scarpa F, Cossu D, et al. A multigene-panel study identifies single nucleotide polymorphisms associated with prostate cancer risk. Int J Mol Sci. 2023;24(8):7594. https://doi.org/10.3390/ijms24087594 .
doi: 10.3390/ijms24087594
pubmed: 37108754
pmcid: 10142258
Blank S, Nienhüser H, Dreikhausen L, et al. Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer. Oncotarget. 2017;8(29):47518–32. https://doi.org/10.18632/oncotarget.17671 .
doi: 10.18632/oncotarget.17671
pubmed: 28537901
pmcid: 5564583
Ngaha TYS, Zhilenkova AV, Essogmo FE, et al. Angiogenesis in lung cancer: understanding the roles of growth factors. Cancers (Basel). 2023;15(18):4648. https://doi.org/10.3390/cancers15184648 .
doi: 10.3390/cancers15184648
pubmed: 37760616
Li X, Liu M, Shi Q, et al. Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma. Hematol Oncol. 2023;41(2):230–8. https://doi.org/10.1002/hon.2993 .
doi: 10.1002/hon.2993
pubmed: 35304777
Kang MA, Lee J, Ha SH, et al. Interleukin4Rα (IL4Rα) and IL13Rα1 are associated with the progress of renal cell carcinoma through janus kinase 2 (JAK2)/forkhead box O3 (FOXO3) pathways. Cancers (Basel). 2019;11(9):1394. https://doi.org/10.3390/cancers11091394 .
doi: 10.3390/cancers11091394
pubmed: 31540495
Aziz S, Ahmed SS, Ali A, et al. Salivary immunosuppressive cytokines IL-10 and IL-13 are significantly elevated in oral squamous cell carcinoma patients. Cancer Invest. 2015;33(7):318–28. https://doi.org/10.3109/07357907.2015.1041642 .
doi: 10.3109/07357907.2015.1041642
pubmed: 26046681
Pastuszak-Lewandoska D, Domańska-Senderowska D, Antczak A, et al. The expression levels of IL-4/IL-13/STAT6 signaling pathway genes and SOCS3 could help to differentiate the histopathological subtypes of non-small cell lung carcinoma. Mol Diagn Ther. 2018;22(5):621–9. https://doi.org/10.1007/s40291-018-0355-7 .
doi: 10.1007/s40291-018-0355-7
pubmed: 30105735
pmcid: 6132440
Krishnan SST, Das SK P, et al. Descriptive epidemiology of gastrointestinal cancers: results from National Cancer Registry Programme, India. Asian Pac J Cancer Prev. 2022;23(2):409–18. https://doi.org/10.31557/APJCP.2022.23.2.409 .
doi: 10.31557/APJCP.2022.23.2.409
pubmed: 35225451
Phukan RK, Chetia CK, Ali MS, Mahanta J. Role of dietary habits in the development of esophageal cancer in Assam, the North-Eastern region of India. Nutr Cancer. 2001;39(2):204–9. https://doi.org/10.1207/S15327914nc392_7 .
doi: 10.1207/S15327914nc392_7
pubmed: 11759281
Shanker N, Mathur P, Das P, Sathishkumar K, Martina Shalini AJ, Chaturvedi M. Cancer scenario in North-East India & need for an appropriate research agenda. Indian J Med Res. 2021;154(1):27–35. https://doi.org/10.4103/ijmr.IJMR_347_20 .
doi: 10.4103/ijmr.IJMR_347_20
pubmed: 34782528
pmcid: 8715693
Simba H, Kuivaniemi H, Abnet CC, Tromp G, Sewram V. Environmental and life-style risk factors for esophageal squamous cell carcinoma in Africa: a systematic review and meta-analysis. BMC Public Health. 2023;23(1):1782. https://doi.org/10.1186/s12889-023-16629-0 .
doi: 10.1186/s12889-023-16629-0
pubmed: 37710248
pmcid: 10500769
Mohan P, Munisamy M, Selvan KS, Hamide A. Esophageal squamous cell cancer in Plummer-Vinson syndrome: is lichen planus a missing link? J Postgrad Med. 2022;68(2):98–9. https://doi.org/10.4103/jpgm.jpgm_375_21 .
doi: 10.4103/jpgm.jpgm_375_21
pubmed: 35417996
pmcid: 9196297
Hu B, Zhu Y, Wu X. Comparison of prognostic factors of esophageal cancer between a Chinese cohort and the Surveillance, Epidemiology, and End Results (SEER) database: a retrospective cohort study. J Gastrointest Oncol. 2022;13(2):527–38. https://doi.org/10.21037/jgo-22-145 .
doi: 10.21037/jgo-22-145
pubmed: 35557583
pmcid: 9086052
He Y, Liang D, Du L, et al. Clinical characteristics and survival of 5283 esophageal cancer patients: a multicenter study from eighteen hospitals across six regions in China. Cancer Commun (Lond). 2020;40(10):531–44. https://doi.org/10.1002/cac2.12087 .
doi: 10.1002/cac2.12087
pubmed: 32845581
Hou H, Meng Z, Zhao X, et al. Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018. Front Oncol. 2019;9:548. https://doi.org/10.3389/fonc.2019.00548 .
doi: 10.3389/fonc.2019.00548
pubmed: 31316913
pmcid: 6610307
Wei MX, Song X, Zhao XK, et al. Clinicopathological characteristics and postoperative prognosis of patients with nuclear pedigree of esophageal squamous cell carcinoma. Front Oncol. 2023;13:1190457. https://doi.org/10.3389/fonc.2023.1190457 .
doi: 10.3389/fonc.2023.1190457
pubmed: 37538122
pmcid: 10396289
Das M, Sharma SK, Sekhon GS, Mahanta J, Phukan RK, Jalan BK. p16 gene silencing along with p53 single-nucleotide polymorphism and risk of esophageal cancer in Northeast India. Tumour Biol. 2017;39(5):1010428317698384. https://doi.org/10.1177/1010428317698384 .
doi: 10.1177/1010428317698384
pubmed: 28459370